Loganathan, S. N., Tang, N., Holler, A. E., Wang, N., & Wang, J. (2019). Targeting the IGF1R/PI3K/AKT pathway sensitizes Ewing sarcoma to BET bromodomain inhibitors. Mol Cancer Ther.
Styl ChicagoLoganathan, Sudan N., Nan Tang, Albert E. Holler, Nenghui Wang, a Jialiang Wang. "Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors." Mol Cancer Ther 2019.
Citace podle MLALoganathan, Sudan N., et al. "Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors." Mol Cancer Ther 2019.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..